Erlotinib is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is Erlotinib Hydrochloride.
| Product ID | 59651-532_3ecafc1e-979a-4aff-a276-18fc0b110491 |
| NDC | 59651-532 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Erlotinib |
| Generic Name | Erlotinib |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2022-06-22 |
| Marketing Category | ANDA / |
| Application Number | ANDA216342 |
| Labeler Name | Aurobindo Pharma Limited |
| Substance Name | ERLOTINIB HYDROCHLORIDE |
| Active Ingredient Strength | 150 mg/1 |
| Pharm Classes | Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2022-06-22 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0093-7662 | Erlotinib | Erlotinib |
| 0093-7663 | Erlotinib | Erlotinib |
| 0093-7664 | Erlotinib | Erlotinib |
| 51991-890 | Erlotinib | Erlotinib Hydrochloride |
| 51991-891 | Erlotinib | Erlotinib Hydrochloride |
| 51991-892 | Erlotinib | Erlotinib Hydrochloride |
| 59651-530 | Erlotinib | Erlotinib |
| 59651-531 | Erlotinib | Erlotinib |
| 59651-532 | Erlotinib | Erlotinib |
| 59923-725 | Erlotinib | Erlotinib |
| 59923-726 | Erlotinib | Erlotinib |
| 59923-727 | Erlotinib | Erlotinib |
| 63304-095 | Erlotinib | Erlotinib |
| 63304-096 | Erlotinib | Erlotinib |
| 63304-135 | Erlotinib | Erlotinib |
| 68382-913 | Erlotinib | Erlotinib |
| 68382-914 | Erlotinib | Erlotinib |
| 68382-915 | Erlotinib | Erlotinib |
| 70771-1521 | Erlotinib | Erlotinib |
| 70771-1522 | Erlotinib | Erlotinib |
| 70771-1523 | Erlotinib | Erlotinib |
| 72485-217 | Erlotinib | Erlotinib hydrochloride |
| 72485-218 | Erlotinib | Erlotinib hydrochloride |
| 72485-219 | Erlotinib | Erlotinib hydrochloride |